FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

Lemon Bottle

Lemon Bottle Fat Dissolve

Weight Loss & Metabolic

Lemon Bottle is a branded lipolytic injection solution that is not a peptide but rather a combination of riboflavin (vitamin B2), bromelain (pineapple-derived enzyme), and lecithin, marketed primarily in the aesthetic medicine market for non-surgical fat dissolution. Originating from South Korea, it has gained rapid popularity in cosmetic clinics worldwide as an alternative to traditional deoxycholic acid-based fat dissolving injections. The product claims to induce adipocyte lipolysis and fat cell destruction through its combined enzymatic and emulsifying components.

Mécanisme d'action

Injectable fat-dissolving solution containing riboflavin, lecithin, and bromelain. Disrupts adipocyte cell membranes.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Administered by trained practitioners. 2-5ml per treatment area, injected subcutaneously. Treatments spaced 2-4 weeks apart.

Notes de recherche

Clinical Research Status

Lemon Bottle has not undergone rigorous peer-reviewed clinical trials or regulatory approval by the FDA, EMA, or other major pharmaceutical regulatory bodies for fat dissolution. The product is marketed as a "lipolytic solution" rather than a pharmaceutical, allowing it to be sold in many jurisdictions without the clinical trial data required for drug approval. Anecdotal clinical results from aesthetic practitioners are widely shared on social media and at industry conferences, but independent verification of efficacy claims remains lacking.

Key Published Findings

No peer-reviewed publications in indexed medical journals have specifically evaluated Lemon Bottle's efficacy or mechanism of action as a combined formulation. Individual components have established biochemistry: bromelain has proteolytic and anti-inflammatory properties, lecithin (phosphatidylcholine) has been studied for injection lipolysis, and riboflavin participates in fatty acid oxidation. However, the specific concentrations, combination ratios, and delivery method used in Lemon Bottle have not been independently validated for fat reduction.

Safety Profile

Reports of adverse effects include significant swelling, bruising, pain at injection sites, skin necrosis in rare cases, and irregular contour deformities when administered improperly. Without standardized clinical trials, the true incidence of complications is unknown and likely underreported in the commercial aesthetic setting. Concerns have been raised by medical professionals regarding the lack of long-term safety data, unknown product consistency between batches, and potential risks of injecting enzymatic compounds into subcutaneous tissue.

Comparison to Related Compounds

Unlike Kybella (deoxycholic acid), which is FDA-approved specifically for submental fat and has completed rigorous Phase III clinical trials, Lemon Bottle has no regulatory approval for any fat reduction indication. Compared to traditional phosphatidylcholine/deoxycholate (PCDC) injection lipolysis, Lemon Bottle claims to produce less swelling and downtime, though this has not been verified in comparative studies. The bromelain component distinguishes it from other lipolytic injectables, theoretically providing enzymatic fat breakdown, but optimal concentrations for subcutaneous injection have not been established.

Community Observations

The aesthetic community is divided on Lemon Bottle, with some practitioners reporting impressive results in small treatment areas while others express concern about the lack of regulatory oversight and clinical evidence. Social media has amplified its popularity, particularly on TikTok and Instagram, leading to widespread use despite medical community reservations. Price points are significantly lower than FDA-approved alternatives, contributing to its market adoption but also raising questions about product quality and manufacturing standards.

Moitié de vie

N/A (not a peptide)

Réconstitution

Pre-mixed solution (no reconstitution)

Conservation

Lyophilisé

Refrigerate 2-8C.

Réconstitué

Use immediately after opening.

Statut légal aux États-Unis

Unregulated cosmetic product

Autres noms connus

Lemon Bottle Fat Dissolve

Questions fréquentes

Qu'est-ce que Lemon Bottle ?

Lemon Bottle is a branded lipolytic injection solution that is not a peptide but rather a combination of riboflavin (vitamin B2), bromelain (pineapple-derived enzyme), and lecithin, marketed primarily in the aesthetic medicine market for non-surgical fat dissolution. Originating from South Korea, it has gained rapid popularity in cosmetic clinics worldwide as an alternative to traditional deoxycholic acid-based fat dissolving injections. The product claims to induce adipocyte lipolysis and fat cell destruction through its combined enzymatic and emulsifying components.

Comment agit Lemon Bottle ?

Injectable fat-dissolving solution containing riboflavin, lecithin, and bromelain. Disrupts adipocyte cell membranes.

Quel est le statut réglementaire de Lemon Bottle aux États-Unis ?

Unregulated cosmetic product

Quelle est la demi-vie de Lemon Bottle ?

N/A (not a peptide)

Sous quels autres noms Lemon Bottle est-il connu ?

Lemon Bottle Fat Dissolve

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète